Loading
4 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Eosinophilic solid and cystic renal cell carcinoma is a recently named kidney cancer, almost always in women, made of pink cells in solid areas and cysts. It was first seen in people with tuberous sclerosis and then found on its own, it is nearly always confined to the kidney, and surgery cures it in almost every reported case.
The 2022 WHO classification introduced eosinophilic solid and cystic renal cell carcinoma as a new morphologically defined type (Moch 2022). It was first described in patients with tuberous sclerosis complex; a search for a sporadic counterpart found 16 morphologically identical tumours, all in women without clinical tuberous sclerosis, median age 57, with solid and macrocystic growth, voluminous eosinophilic cytoplasm with granular stippling, hobnail cyst lining, nuclear PAX8, a CK20-positive and CK7-negative phenotype and no CD117; 13 of 16 were stage pT1 (Am J Surg Pathol 2016). In 19 further cases, all women, median age 55 and median size 31 mm, CK20 was positive in 74 percent, 89 percent were pT1, and 15 of 16 with follow-up were alive without disease (Am J Surg Pathol 2017). Sporadic cases carry somatic TSC1 or TSC2 mutations, the same pathway as the syndromic form.
How it differs from its parent: a female-only series, tuberous sclerosis biology (mTOR pathway), CK20 positivity and an indolent course with rare metastasis; it is distinguished from oncocytoma and chromophobe carcinoma by the cysts, the stippled cytoplasm and CK20.
| Setting | Approach | Guideline |
|---|---|---|
| All stages | Partial nephrectomy; everolimus is the rational choice for rare metastatic disease on the tuberous sclerosis biology, without trial evidence. | not mapped |